What is the official website of Novartis Europe ?

The official website of Novartis Europe is https://www.novartis.com/.

What is Novartis Europe's cybersecurity risk score?

Novartis Europe has an AI-generated cybersecurity risk score of 749 out of 1000, indicating a Moderate security posture according to Rankiteo's assessment.

How many security incidents has Novartis Europe experienced?

According to Rankiteo, Novartis Europe currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Europe been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Europe has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Europe have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Europe is not certified under SOC 2 Type 1.

Does Novartis Europe have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Europe does not hold a SOC 2 Type 2 certification.

Does Novartis Europe comply with GDPR ?

According to Rankiteo, Novartis Europe is not listed as GDPR compliant.

Does Novartis Europe have PCI DSS certification ?

According to Rankiteo, Novartis Europe does not currently maintain PCI DSS compliance.

Does Novartis Europe comply with HIPAA ?

According to Rankiteo, Novartis Europe is not compliant with HIPAA regulations.

Does Novartis Europe have ISO 27001 certification ?

According to Rankiteo,Novartis Europe is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Europe operate in ?

Novartis Europe operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Europe have ?

Novartis Europe employs approximately 1 people worldwide.

Does Novartis Europe own any subsidiaries ?

Novartis Europe presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Europe have ?

Novartis Europe's official LinkedIn profile has approximately 2,367 followers.

What is the NAICS classification code for Novartis Europe ?

Novartis Europe is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Europe have a Crunchbase profile ?

No, Novartis Europe does not have a profile on Crunchbase.

Does Novartis Europe have a LinkedIn profile ?

Yes, Novartis Europe maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-europe.

How many cybersecurity incidents has Novartis Europe experienced ?

As of July 4, 2026, Rankiteo reports that Novartis Europe has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Europe have ?

Novartis Europe has an estimated 5,700 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Europe faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack and Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Europe

Boost Score +25 with badge (5 left)

749

/1000

Moderate

774

/1000

Fair

Novartis Europe Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

A healthier future starts with bold action. Our 31,000+ employees in Europe are turning science into impact every day. We are working with policymakers to improve healthcare access, collaborating to drive breakthroughs and transforming lives through science and innovation. Join the conversation and discover how we're working towards a healthier Europe.

Novartis Europe A.I CyberSecurity Scoring

Scoring History

Novartis Europe

Novartis Europe CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Europe

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Europe Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Europe

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Europe in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Europe in 2026.

Incident Types Novartis Europe vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Europe in 2026.

Incident History - Novartis Europe (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Europe Subsidiaries

Novartis Europe

Pharmaceutical Manufacturing

Website: https://www.novartis.com/

Company Size: 1

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis MalaysiaPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Loading…

Novartis Europe Similar Companies

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Loading…

NEWS

Novartis Europe CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-58523

SUMMARY

Improper access control in Microsoft Edge for Android allows an unauthorized attacker to bypass a security feature over a network.

Published

Date2026-07-03

Updated

Date2026-07-03

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-58523

CVE-2026-14617

SUMMARY

A security vulnerability has been detected in NousResearch hermes-agent up to 2026.4.30. Affected is the function GatewayStreamConsumer._filter_and_accumulate of the file gateway/stream_consumer.py of the component Streaming Reasoning Tag Filter. The manipulation leads to improper handling of case sensitivity. The attack may be initiated remotely. The attack's complexity is rated as high. The exploitability is told to be difficult. The exploit has been disclosed publicly and may be used. The project decided to not implement a dedicated fix: "[T]he analysis and the fix are both sound. It just lands below the bar for the maintenance cost of a duplicated scrub path."

Published

Date2026-07-03

Updated

Date2026-07-03

RISK INFORMATION (Score: 3.1)

cvss2

Base Score: 2.1

Complexity: HIGH

AV:N/AC:H/Au:S/C:P/I:N/A:N

cvss3

Base Score: 3.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 1.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.6

REFERENCES

CVE-2026-58597

SUMMARY

Insufficient ui warning of dangerous operations in Microsoft Edge (Chromium-based) allows an unauthorized attacker to perform spoofing over a network.

Published

Date2026-07-03

Updated

Date2026-07-03

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-58597

CVE-2026-58524

SUMMARY

Improper neutralization of input during web page generation ('cross-site scripting') in Microsoft Edge (Chromium-based) allows an unauthorized attacker to perform spoofing over a network.

Published

Date2026-07-03

Updated

Date2026-07-03

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-58524

CVE-2026-58522

SUMMARY

Relative path traversal in Microsoft Edge for Android allows an unauthorized attacker to disclose information locally.

Published

Date2026-07-03

Updated

Date2026-07-03

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:H/I:L/A:N

Impact Score

4.2

Exploitability

2.5

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-58522

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…